Khunti et al. observed an improvement in COVID-19 outcomes among patients taking metformin and a greater risk of adverse outcomes associated with insulin use in a nationwide cohort of individuals with T2DM [21]. The gene discussed is INS; the disease is type 2 diabetes mellitus.